LLY · Eli Lilly and Company
$935.622026-05-17Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Very High Uncertainty
Bull
$2590
+176.8% vs market
Base · active
$935
-0.1% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($593 · $2590) Analysts Range ($985 · $1350) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $28.3B | — | 34.1% | 9.3% | $8.8B | −$5.4B | $3.3B | 4.1% | — | 52.7% | $16.6B | $6.22 | — |
| 2022.Q4 | $28.5B | 0.8% | 36.9% | 8.3% | $9.7B | −$5.2B | $4.5B | 5.9% | — | 57.1% | $17.2B | $6.95 | — |
| 2023.Q4 | $34.1B | 19.6% | 38.5% | 20.1% | $10.5B | −$15.1B | −$4.6B | 5.7% | — | 53.1% | $22.3B | $5.84 | — |
| 2024.Q4 | $45.0B | 32.0% | 47.3% | 16.5% | $17.8B | −$18.2B | −$398MM | 6.4% | — | 73.1% | $26.4B | $11.79 | — |
| 2025.Q4 | $65.2B | 44.7% | 55.5% | 19.8% | $29.0B | −$21.1B | $7.9B | 6.2% | — | 99.4% | $32.0B | $22.98 | 23.2 |
| italics below = DCF projection · 10yr Rev CAGR: 9.9% |
| 2026.Q4 | $81.7B | +25.3% | 67.5% | 19.8% | $44.2B | −$18.9B | $25.3B | 6.3% | $23.8B | 106.7% | $50.9B | $33.24 | 28.1 |
| 2027.Q4 | $94.8B | +16.1% | 63.1% | 19.8% | $48.0B | −$10.4B | $37.6B | 6.5% | $33.2B | 85.5% | $61.4B | $36.60 | 25.6 |
| 2028.Q4 | $106.4B | +12.2% | 58.8% | 19.9% | $50.1B | −$7.0B | $43.1B | 6.7% | $35.7B | 77.3% | $68.4B | $38.85 | 24.1 |
| 2029.Q4 | $117.2B | +10.1% | 54.4% | 19.9% | $51.1B | −$8.7B | $42.4B | 7.0% | $32.8B | 70.3% | $77.0B | $40.35 | 23.2 |
| 2030.Q4 | $126.6B | +8.0% | 50.0% | 19.9% | $50.8B | −$7.0B | $43.8B | 7.2% | $31.6B | 63.1% | $84.0B | $38.34 | 24.4 |
|
| Term. Yr+ | $173.6B | 4.1% | 41.3% | 20.0% | $57.4B | −$10.0B | $47.4B | 8.6% | $520.1B | 23.6% | — | — | — |
Active scenario IV: $935 (-0.1% vs market)